SRNE - Sorrento on go with early-stage COVID-19 antibody study

Sorrento Therapeutics ([[SRNE]] +4.1%) nabs FDA sign-off for its Phase 1 trial for intravenous ((IV)) STI-2020 (COVI-AMG) that will evaluate the safety, pharmacokinetics and efficacy of a single injection of STI-2020 in healthy volunteers and outpatient COVID-19 patients with mild symptoms.The company previously announced that STI-2020 demonstrated a complete neutralizing effect at a very low dose in preclinical studies. Sorrento has initiated manufacturing to produce up to 100,000 doses in anticipation of a potential emergency use authorization.In November, the company filed investigational new drug application for STI-2020.

For further details see:

Sorrento on go with early-stage COVID-19 antibody study